Publication: Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in Thailand
Issued Date
2005-03-31
Resource Type
ISSN
0264410X
Other identifier(s)
2-s2.0-20044364751
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine. Vol.23, No.19 (2005), 2522-2529
Suggested Citation
Chitraporn Karnasuta, Robert M. Paris, Josephine H. Cox, Sorachai Nitayaphan, Punnee Pitisuttithum, Prasert Thongcharoen, Arthur E. Brown, Sanjay Gurunathan, James Tartaglia, William L. Heyward, John G. McNeil, Deborah L. Birx, Mark S. De Souza Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. Vol.23, No.19 (2005), 2522-2529. doi:10.1016/j.vaccine.2004.10.028 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/16367
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in Thailand
Abstract
Antibody-dependent cell-mediated cytotoxicity (ADCC) was assessed in volunteers participating in an ALVAC-HIV (vCP1521)/AIDSVAX® B/E gp120 prime-boost vaccine trial in Thailand. ADCC activity was measured using chromium release from gp120 subtype B- and CRF01_AE-coated targets in 95 vaccinees and 28 placebo recipients. There was a significant difference in the magnitude of the ADCC response to both targets between vaccinees and placebo recipients. The frequency of responders to subtype B and to CRF01_AE was 96% and 84% in the vaccine group versus 11% and 7% in the placebo group. The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease.